Drug Type Dendritic cell vaccine |
Synonyms Cytotoxic T-cell therapy, Dendritic cell therapy, MASCT I + [6] |
Target- |
Mechanism Cytotoxic T lymphocytes stimulants, Immunologic cytotoxicity, Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Desmoplastic Small Round Cell Tumor | Phase 2 | CN | 01 Feb 2024 | |
Endometrial Stromal Sarcoma | Phase 2 | CN | 01 Feb 2024 | |
Hemangiosarcoma | Phase 2 | CN | 01 Feb 2024 | |
Leiomyosarcoma | Phase 2 | CN | 01 Feb 2024 | |
Liposarcoma | Phase 2 | CN | 01 Feb 2024 | |
Malignant Fibrous Histiocytoma | Phase 2 | CN | 01 Feb 2024 | |
Neurofibrosarcoma | Phase 2 | CN | 01 Feb 2024 | |
Rhabdomyosarcoma | Phase 2 | CN | 01 Feb 2024 | |
Synovial Sarcoma | Phase 2 | CN | 01 Feb 2024 | |
Soft Tissue Sarcoma | Phase 2 | CN | 10 Jan 2024 |
Phase 1 | 39 | gjxbneqvlx(eyppivendy) = gdmnwagugp lhujiakkmy (teqlhapjtv ) View more | Positive | 26 May 2023 |